RecruitingNot ApplicableNCT06421142

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

Application Research of FAPI Positron Emission Tomography(PET)/MRI, 18F-Fluorodeoxyglucose (FDG) PET/MRI, and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy

Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

80 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Urinary Bladder Neoplasms

Summary

The aim of this trial is to investigate the value of FAPI PET/MRI, FDG PET/MRI and MRI in diagnosing MIBC and predicting the efficacy of neoadjuvant therapy for MIBC patients, so as to guide the clinic to adjust the treatment plan in time and benefit MIBC patients.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is testing two advanced imaging techniques — FAPI PET/MRI and FDG PET/MRI — to improve diagnosis and treatment planning for muscle-invasive bladder cancer. These scans can detect cancer activity in ways that standard imaging may miss. **You may be eligible if...** - You have suspected or confirmed muscle-invasive bladder cancer - You are able to complete all required imaging scans - You have complete medical records and lab results available **You may NOT be eligible if...** - You have another active cancer at the same time - You are not planning to have surgery - You have already received neoadjuvant (pre-surgery) therapy for bladder cancer - You have a known allergy to the imaging contrast agents - You have serious other medical conditions preventing scans Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREimaging examinations:FAPI PET/MRI, FDG PET/MRI, MRI

FAPI PET/MRI and FDG PET/MRI examination Data acquisition was performed using a GE Healthcare SIGNA PET/MR instrument. Enrolled patients were injected intravenously with 68Ga-FAPI or 18F-FDG tracer and underwent simultaneous PET and MRI scanning approximately 30-60 minutes after intravenous administration of the tracer at a dose of 1.85-3.7 MBq/kg. MRI examination MRI examination was performed using a Skyra 3.0T MRI scanner from Siemens, Germany, with a 16-channel phased-array surface coil, and the scanning range was from the superior margin of the iliac wing to the inferior margin of the pubic symphysis.